Remidex Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 3.00 Cr
- Company Age 43 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.00 Cr
- Satisfied Charges ₹ 15.26 Cr
- Revenue Growth 18.50%
- Profit Growth 14.52%
- Ebitda 5860.85%
- Net Worth -37.44%
- Total Assets -17.16%
About Remidex Pharma
Remidex Pharma Private Limited (RPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 15 June 1981 and has a history of 43 years and eight months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹6.00 Cr. The company has closed loans amounting to ₹15.26 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nilima Rao, Nandan Rao, and Ishaan Rao serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24231KA1981PTC004260
- Company No.
004260
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 1981
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Remidex Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilima Rao  | Managing Director | 24-Jan-2017 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ishaan Rao | Director | 24-Oct-2018 | Current |
| Nandan Rao | Director | 24-Oct-2018 | Current |
Financial Performance of Remidex Pharma.
Remidex Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 18.5% increase. The company also saw a substantial improvement in profitability, with a 14.52% increase in profit. The company's net worth observed a substantial decline by a decrease of 37.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Remidex Pharma?
Unlock access to Remidex Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Ishaan Labs Private LimitedNilima Rao, Nandan Rao and 1 more are mutual person
- Sanil Pharmaceuticals Private Limited
Nilima Rao, Nandan Rao and 1 more are mutual person
Charges (Loans)
₹6.00 Cr
₹15.26 Cr
Charges Breakdown by Lending Institutions
- Canara Bank : 6.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Apr 2006 | Canara Bank | ₹6.00 Cr | Open |
| 21 Aug 2019 | Others | ₹6.00 Cr | Satisfied |
| 20 Jul 2018 | Canara Bank | ₹3.10 M | Satisfied |
| 29 Jan 2005 | Kotak Mahindra Bank Limited | ₹3.35 Cr | Satisfied |
| 29 Jan 2005 | Kotak Mahindra Bank Ltd | ₹1.95 Cr | Satisfied |
How Many Employees Work at Remidex Pharma?
Remidex Pharma has a workforce of 138 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Remidex Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Remidex Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
